|
References  |
|
|
| *references marked with an asterisk below are user-added references |
|
U.S. References |
|
|
| Add a new US reference: |
| | Reference | Relevancy | Comments | Reference | Relevancy | Comments | 5645587 Chanda 424/423 Jul,1997 |      Your vote accepted [0 after 0 votes] | | 5595571 Jaffe 8/94.11 Jan,1997 |      Your vote accepted [0 after 0 votes] | | 5507810 Prewett 128/898 Apr,1996 |      Your vote accepted [0 after 0 votes] | | 5476516 Seifter
Dec,1995 |      Your vote accepted [0 after 0 votes] | | 5447536 Girardot 8/94.11 Sep,1995 |      Your vote accepted [0 after 0 votes] | | 5437287 Phillips 128/898 Aug,1995 |      Your vote accepted [0 after 0 votes] | | 5436291 Levy 524/706 Jul,1995 |      Your vote accepted [0 after 0 votes] | | 5296583 Levy
Mar,1994 |      Your vote accepted [0 after 0 votes] | | 5147514 Mechanic 204/157.68 Sep,1992 |      Your vote accepted [0 after 0 votes] | | 5104405 Nimni
Apr,1992 |      Your vote accepted [0 after 0 votes] | | 5094661 Levy 8/94.11 Mar,1992 |      Your vote accepted [0 after 0 votes] | | 5075112 Lane
Dec,1991 |      Your vote accepted [0 after 0 votes] | | 5002566 Carpentier 600/36 Mar,1991 |      Your vote accepted [0 after 0 votes] | | 4976733 Girardot 623/11.11 Dec,1990 |      Your vote accepted [0 after 0 votes] | | 4830847 Benedict 424/1.45 May,1989 |      Your vote accepted [0 after 0 votes] | | 4801299 Brendel 623/1.47 Jan,1989 |      Your vote accepted [0 after 0 votes] | | 4798611 Freeman, Jr. 600/36 Jan,1989 |      Your vote accepted [0 after 0 votes] | | 4776853 Klement 8/94.11 Oct,1988 |      Your vote accepted [0 after 0 votes] | | 4729139 Nashef 8/94.11 Mar,1988 |      Your vote accepted [0 after 0 votes] | | 4603006 Sikes 252/180 Jul,1986 |      Your vote accepted [0 after 0 votes] | | 4553974 Dewanjee 8/94.11 Nov,1985 |      Your vote accepted [0 after 0 votes] | | 4405327 Pollock 8/94.11 Sep,1983 |      Your vote accepted [0 after 0 votes] | | 4404181 Mauthner 435/40.52 Sep,1983 |      Your vote accepted [0 after 0 votes] | | 4402697 Pollock 8/94.11 Sep,1983 |      Your vote accepted [0 after 0 votes] | | 4323358 Lentz 8/94.11 Apr,1982 |      Your vote accepted [0 after 0 votes] | | 4319363 Ketharanathan 623/1.47 Mar,1982 |      Your vote accepted [0 after 0 votes] | | |
|
|
|
|
U.S. References |
|
|
Foreign References |
|
|
|
|
|
|
Foreign References |
|
|
Other References |
|
|
|
|
|
|
Other References |
|
|
|
|
|
References  |
|
|
Claims  |
|
|
I claim:
1. A method of preparing biological tissue comprising the steps of:
a. providing a biological tissue having reactive groups that will react
with an aldehyde;
b. treating the biological tissue with the aldehyde, reacting the aldehyde
with the reactive groups, producing substituents on the tissue selected
from the group consisting of free aldehyde groups, Schiff's bases, and
combinations thereof;
c. dehydrating the tissue; and,
d. treating the tissue with a borohydride, selected from the group
consisting of sodium and potassium borohydride, in a polar organic solvent
at a pH of less than about 8 to reduce the substituents on the tissue.
2. The method of claim 1 further comprising the step of washing the tissue
with the polar organic solvent to remove the borohydride from the tissue.
3. The method of claim 2 further comprising the step of rehydrating the
tissue.
4. The method of claim 1 wherein the biological tissue is selected from the
group consisting of mammalian pericardium, mammalian heart valves and
mammalian vascular grafts.
5. The method of claim 1 wherein the aldehyde is glutaraldehyde and the
polar organic solvent is ethanol.
6. The method of claim 1 wherein the step of dehydrating the tissue
comprises the step of treating the tissue with the polar organic solvent.
7. The method of claim 6 wherein the polar organic solvent is selected from
the group consisting of ethanol, isopropanol, acetonitrile and pyridine.
8. The method of claim 7 wherein the step of treating the tissue with a
polar organic solvent comprises treating the tissue with increasingly
anhydrous solutions of the polar organic solvent.
9. The method of claim 1 wherein the step of treating the tissue with a
borohydride is carried out under anhydrous conditions.
10. The method of claim 3 wherein the step of rehydrating the tissue
comprises treating the tissue with increasingly dilute concentrations of
the polar organic solvent in aqueous solution.
11. The method of claim 1, further comprising the step of sterilizing the
biological tissue.
12. The method of claim 11, further comprising the step of treating the
tissue with heparin.
13. The method of claim 1, further comprising the step of using the tissue
to make a bioprosthetic implant.
14. The method of claim 1 wherein the borohydride is sodium borohydride.
15. A method of preparing biological tissue comprising the steps of:
a. providing a dehydrated biological tissue having substituents selected
from the group consisting of free aldehyde groups, Schiff's bases, and
combinations thereof; and,
b. treating the tissue with a borohydride, selected from the group
consisting of sodium borohydride and potassium borohydride, in a polar
organic solvent at a pH of less than about 8 to reduce the substituents.
16. The method of claim 14 further comprising the step of washing the
tissue with the polar organic solvent to remove the borohydride from the
tissue.
17. The method of claim 15 further comprising the step of rehydrating the
tissue.
18. The method of claim 14 wherein the borohydride is sodium borohydride.
19. The method of claim 14 wherein the polar organic solvent is selected
from the group consisting of ethanol, isopropanol, acetonitrile and
pyridine.
20. The method of claim 19 wherein the polar organic solvent is ethanol. |
|
|
|
|
Claims  |
|
|
Description  |
|
|
FIELD OF INVENTION
The invention is in the field of processes for preparing biological tissues
of extracellular matrices for implantation as bioprosthetic implants. The
invention relates to a process for using sodium or potassium borohydride
to modify reactive chemical groups in biological tissues or protein
matrices that have been cross-linked or treated by aldehydes or other
chemical reagents.
BACKGROUND
Treatment of biological tissues with glutaraldehyde is a preferred method
for manufacturing bioprosthetic implants. Glutaraldehyde forms cross-links
and polymers with a variety of matrix components of biological tissues,
rendering these tissues less immunogenic when implanted in a living host.
Glutaraldehyde cross-linking also alters the mechanical properties of
biological tissues.
Glutaraldehyde cross-linked porcine heart valves and bovine pericardial
tissues have been used as material for bioprosthetic human heart valves.
Glutaraldehyde treated blood vessels and pericardial patches have also
been used in other applications.
Glutaraldehyde treated biological tissues, especially porcine heart valves
and bovine pericardial tissues, have been used as materials for
bioprosthetic heart valves for more than 20 years. It has become evident
that calcification of the glutaraldehyde treated bioprosthetic heart
valves has been a major cause of long term device failure.
The exact mechanism underlying the calcification of glutaraldehyde treated
heart valves is not known. It has been suggested that the toxicity of the
glutaraldehyde polymers or the breakdown products of the glutaraldehyde
polymers cause the death of connective tissue cells arriving at the
implant site. The remnants of these dead cells may then act as nidi for
the nitiation of calcificaiton. The toxicity of the glutaraldehyde
polymers which leach out to tissue surrounding a glutaraldehyde
cross-linked bio-implant may, through a similar mechanism, further
complicate the integration of the implant into the host tissue. The free
aldehyde groups of the glutaraldehyde polymers may contribute to the
toxicity of the polymers.
A variety of approaches have been taken to counteract calcification of
glutaraldehyde treated implants. For example, aldehyde treated tissues
have been reacted with polyols (U.S. Pat. No. 5,476,516, issued to Seitter
et al., 19 Dec. 1995), treated with alipathic carboxylic acids (U.S. Pat.
No. 4,976,733 issued to Girardot 11 Dec, 1990) treated with partially
degraded heparin (U.S. Pat. No. 5,645,587 issued to Chanda et al. 8 Jul.
1997), treated with sodium dodecyl sulfate (U.S. Pat. No. 4,323,358 issued
to Lentz et al. 6 Apr. 1982), treated with polysaccharides, disphsphonates
or phosphoproteins (U.S. Pat. No. 5,104,405 to Nimni 14 Apr. 1992),
impregnated with ferric or stannic salts (U.S. Pat. No. 5,002,566 to
Carpentier et al. 26 Mar. 1991), and treated with trivalent aluminum
cations (U.S. Pat. No. 5,094,661 to Levy et al. 10 Mar. 1992).
Sodium borohydride in aqueous solution is a known reducing agent. Sodium
borohydride in solution has previously been used as a reducing agent to
treat glutaraldehyde fixed tissues. U.S. Pat. No. 4, 553,974 issued to
Dewanjee on 19 Nov. 1985 discloses a process for treatment of
glutaraldehyde fixed tissue with a calcification inhibiting agent, and
then reducing the tissue with sodium borohydride. The calcification
inhibiting agent contains reactive amino groups that bond to free reactive
groups in the fixed tissue. Dewanjee '974 discloses a variety of amino
diphosphonate compounds as effective calcification inhibiting agents (as
do U.S. Pat. Nos. 5,296,583 and 5,436,291 issued to Levy et al. on 22 Mar.
1994 and 25 Jul. 1995 respectively). Dewanjee '974 teaches that a solution
of sodium borohydride may be used to stabilize the bonding of such amino
diphosphonates and glutaraldehyde to protein molecules.
Chen et al. ("Effect of 2-amino oleic acid exposure conditions on the
inhibition of calcification of glutaraldehyde cross-linked porcine aortic
valves" Journal of Biomedical Materials Research, Vol. 28, 1485-1495
(1994)) teach that the use of a sodium borohydride solution alone to treat
glutaraldehyde fixed aortic tissues is not effective to reduce
calcification in the rat subdermal implant model. In fact, when used on
aortic wall tissue, the sodium borohydride treatment resulted in increased
calcification compared to controls with no treatment.
SUMMARY OF THE INVENTION
The invention provides a method of preparing biological tissue that
includes the following steps:
(1) providing a biological tissue having reactive groups that will react
with an aldehyde. The biological tissue may be fibrous material derived
from animal origins, such as mammalian pericardium.
(2) Treating the biological tissue with an aldehyde, such as glutaraldehyde
or other polymeric forms of aldehydes, or polymers containing aldehydes
and/or ketones. Biological tissues containing collagen and other proteins
may be cross-linked by such treatment. Following such treatment, the
tissue typically includes substituents such as aldehyde groups and
Schiff's bases.
(3) Dehydrate the biological tissue. The tissue may be dehydrated by
treating it with a polar organic solvent, such as ethanol, increasingly
anhydrous solutions of the polar organic solvent may be used for this
purpose.
(4) Treating the tissue with sodium or potassium borohydride in a polar
organic solvent at a pH of less than about 8 to reduce substituents on the
tissue such as free aldehyde groups and Schiff bases.
Additional steps may be useful:
Following treatment of the tissue with the borohydride, the borohydride may
be removed from the tissue. Removal of the borohydride may be accomplished
by extraction into an appropriate organic solvent (such as ethanol, other
alcohols, acetonitrile or pyridine). Removal of the hydride from the
tissue may be used to stop the reduction reaction.
To prepare tissue treated in accordance with the invention for use, the
tissue may be rehydrated. For example, the tissue may be treated with
increasingly dilute concentrations of a polar organic solvent in aqueous
solution.
The concentration of reactants, pH, temperature of reaction and duration of
reaction are all parameters of the process of the invention that may be
varied by those skilled in this art in order to vary the results achieved
with the process of the invention. Generally, the reduction should be
carried out at temperatures below those which can cause macromolecules in
the tissue to loose their tertiary and quaternary structures. The
reduction may preferably be carried out for a sufficient period of time,
and under appropriate conditions, to reduce substantially all of the
aldehydes and Schiff's bases in the tissue. A quantity of borohydride may
be used that is approximately stoichiometrically equivalent to the
theoretical amount of aldehydes and Schiff'bases in the tissue. The
borohydride may be provided in an amount that exceeds the saturation
concentration of the borohydride in the polar organic solvent. Providing
such an excess of borohydride may help to ensure that there is a continual
supply of the sodium borohydride as the reduction reaction progresses.
In a preferred embodiment, dehydration may be performed in a stepwise
procedure by immersing the biological tissues in a series of solutions
with increasing concentrations of alcohol (or other polar organic
solvents) in water, or in a continuously concentrating solvent solution,
such as a gradient solution system. As the final dehydration step, the
tissues may be immersed in 100% alcohol. The alcohol may be aspirated away
from the tissue and a solution of sodium borohydride in 100% alcohol added
to the dehydrated biological material. Reduction of the tissues with
borohydride may be allowed to proceed at 4.degree. C. for approximately 24
hours (overnight), fresh sodium borohydride in ethanol solution may then
be added and the reaction continued at 4.degree. C. for a further period
of approximately 24 hours (overnight). The borohydride solution may then
be aspirated away from the tissues. The excess borohydride in the tissue
may be extracted by washing the tissues in 100% alcohol. The borohydride
reduced material may then be rehydrated by immersing the material in a
series of alcohol solutions with decreasing concentrations of alcohol in
water.
The process of the present invention reduces the aldehyde groups in an
aldehyde treated biological tissue to improve the biocompatability of the
tissue. Although the process uses a strong reducing agent, sodium or
potassium borohydride, the structural integrity of the tissues is
preserved, as evidenced by the results disclosed herein. Accordingly, use
of the borohydride in accordance with the process of the invention does
not appear to adversely affect structural components of the tissues.
However, if borohydride is used to reduce tissues in methods which differ
from the process of the present invention, adverse effects on the
structural components of the tissues, such as collagen, elastin or
proteoglycan, may occur.
The process of the invention has the additional advantage of stabilizing
the potentially reversible Schiff's base cross-links between the aldehyde
and the treated tissues, for example between glutaraldehyde polymers and
protein components of the tissue. It has been shown that glutaraldehyde
cross-linked biological tissues release toxic components to cells in vitro
even after extensive and prolonged washing (up to 6 months). This is
evidence that the attachment of glutaraldehyde or its polymers to tissue
fibers is reversible. The reversibility of the reaction is counteracted by
reducing the Schiff's bases. This reduction, converting the C.uparw.N
double bond to a C-N single bond also increases the rotational freedom of
the glutaraldehyde polymer which is attached to the tissue fibre. This
aspect of the reduction of the Schiff's bases may underlie another
unanticipated advantage of the invention: the glutaraldehyde cross-linked
biological tissue after reduction has a compliance characteristic closer
to native tissue than non-reduced tissue.
Biological tissues reduced in accordance with the invention may be used as
implanted materials, such as heart valve prostheses, patches or conduits.
In addition, such tissues may be used in other biological processes,
including instrumentation and biological test support materials.
DETAILED DESCRIPTION
Glutaraldehyde treated bovine pericardia were prepared by immersing freshly
harvested pericardial tissue in glutaraldehyde solution in phosphate
buffered saline for several days. The glutaraldehyde tissues were
dehydrated by immersing the tissues in 25% ethanol in water (tissue:
volume=5 g wet weight: 100 ml) for 15 minutes the 25% ethanol was
aspirated and a 50% ethanol solution was added. After 15 minutes the 50%
ethanol was aspirated and a 75% ethanol was added. After another 15
minutes the 75% ethanol was aspirated and 100% ethanol was added. In the
same manner the 100% ethanol was aspirated and replaced by new 100%
ethanol two additional times.
Those skilled in the art of this invention will understand that there are a
variety of ways in which a tissue may be dehydrated in accordance with
this invention. The dehydration step should preferably remove as much
water as possible, since the presence of water will interfere with the
aldehyde reduction reaction. The tissue may be dehydrated by treating it
with polar organic solvents other than ethanol, such as other alcohols
like isopropanol (because of their physical properties, methanol and
alcohols with more than four carbons would generally not be practical as
the major constituents of the dehydrating agent), acetonitrile, pyridine
or mixtures of such solvents. Such solvents may be selected in accordance
with the present invention by virtue of their ability to extract water
from the treated tissue, while not reacting adversely with the tissue.
Increasingly anhydrous solutions of the polar organic solvent may be used
for this purpose. In each case, it will be appreciated that the efficacy
of the dehydrating agent may be tested according to its ability to dry the
tissue while not interfering with the other aspects of the process of the
invention.
Dehydration of glutaraldehyde treated tissues prior to reduction with
borohydride is an important aspect of the invention. Sodium or potassium
borohydride may reduce aldehydes, Schiff's bases and similar functional
groups in aqueous solution and neutral pH. However, under these
conditions, the borohydrides are very labile and are themselves readily
hydrolyzed by water. Another difficulty is that such a reduction reaction
generates hydrogen gas as a by-product which can be trapped in the tissue
matrices. As the trapped gas accumulates as bubbles in the matrices, the
bubbles may disrupt the tissue matrices as well as create physical voids.
They may also create physical barriers for fluid diffusion, preventing
reduction agents from entering the tissue. In addition, bubbles may make
it difficult for reduction by-products to diffuse out of the tissue, thus
causing a rise of the pH in the micro environment inside the tissue. When
the pH of a borohydride solution rises above 8, cleavage of peptide bonds
may occur. The cleavage of peptide bonds would significantly weaken the
tissue's fibrous structure. It is therefore important to control the pH
environment of the reduction reaction and prevent the formation of trapped
hydrogen gas bubbles.
To initiate the reduction reaction, the 100% ethanol is aspirated and
sodium or potassium borohydride reduction reagent added. In a preferred
embodiment, the reduction reagent may be prepared by adding 0.2 grams of
sodium borohydride to 100 ml of 100% ethanol. The reduction reaction may
be allowed to continue at 4.degree. C. for approximately 24 hours
(overnight). Fresh reduction reagent may then be added and the reaction
continued at 4.degree. C. for a further period of approximately 24 hours
(overnight). It will be appreciated that the duration and conditions of
the reduction reaction are preferably sufficient to ensure that
substantially all of the free aldehydes in the tissue are reduced.
To control pH in accordance with the present invention during the reduction
reaction, the pH of the reducing reaction solution may be monitored. If
the pH rises to 8 or above, the sodium borohydride solution may be removed
and replaced with a fresh solution of sodium borohydride (preferably
sodium borohydride in ethanol).
At the end of the reduction reaction, the reduction reagent may be
aspirated and 100% ethanol used to wash the tissues for 15 min. The
washing procedure may be repeated two more times. The washed tissues were
re-hydrated by removing the 100% ethanol by aspiration and adding a 75%
ethanol solution. Fifteen minutes later, the 75% ethanol was aspirated and
a 50% ethanol solution was added. The reduced tissues were then stored in
50% ethanol.
For use, the tissue treated in accordance with the method of the invention
may be sterilized. The tissue may also be treated with heparin, for
example by dipping in a heparin bath. In one embodiment, the tissue is
sterilized and then treated with heparin.
In accordance with known techniques for using glutaraldehyde fixed tissues,
tissues treated in accordance with the invention may be fashioned into a
variety of bioprosthetic implants, such as heart valves and pericardial
patches.
For evaluation of the reduced tissues by in vitro and in vivo tests, as
disclosed below, tissue samples were immersed and rinsed in phosphate
buffered saline at 4.degree. C. for 15 min. The reduced tissues appear
white and very flexible, unexpectedly resembling fresh non-glutaraldehyde
treated tissues.
The effectiveness of the reduction reaction in reducing free aldehydes was
determined by immersing a piece of the reduced tissue in Fuchsin-sulfite
reagent (Schiff's reagent) for 15 min. Non-reduced tissues turn pink and
purple quickly. Reduced tissue samples remain white and turned slightly
pink after one hour, indicating that the concentration of free aldehydes
in the tissue had been substantially reduced.
The integrity of collagen fibers in the reduced tissues was tested by
several methods. The first method evaluated the quarter scattered banding
of collagen fibers using transmission electron microscopy. Reduced tissues
were dehydrated and embedded in epoxy resin directly prior to sectioning
and staining. The resulting electron micrographs show that the collagen
fibers in the reduced tissues were intact since the banding pattern
appeared normal.
The second method was to compare the shrink temperature of the reduced
samples with that of the native fresh tissues as well as tissues
cross-linked with glutaraldehyde but not reduced. Tissues were sandwiched
between two glass slides (using the glass slides as support) and immersed
in physiological 0.9% saline. The saline was gradually heated at
approximately 1.degree. C. per minute. The length of the tissue strips
were measured at frequent intervals. The exact temperature at which the
tissue's shrinkage rate was at least 1 mm/min was recorded as the shrink
temperature. From this inflection point on a tissue length vs. temperature
graph the shrinkage rate increases dramatically. The results show that the
shrink temperature of the reduced tissues was 79.4.degree..+-.0.3.degree.
C. compared to 83.7.degree..+-.0.2.degree. C. for the non-reduced
cross-linked tissues and 62.3.degree..+-.0.5.degree. C. for the fresh
native tissues. These results provide evidence that the collagen fibers as
well as the bulk of the glutaraldehyde cross-links remain intact following
reduction of the tissue.
The mechanical properties of the reduced tissues were examined by two
different methods. In the first method, dumb-bell shaped tissues were
stamped from pericardial tissues treated by glutaraldehyde and
post-glutaraldehyde reduction. The tissues were pulled on an Instron
Instrument at a load speed of 10 mm/minute. The results in Table 1 show
that there is no significant difference between the stress/strain ratios
of the two groups. There is also no difference in the maximum load
strength of the two groups. In the second method, tissues were pulled to
2.5 kg and held at that distance for 15 min. while the reduction in load
was measured. The result in Table 2 shows that the initial slope of the
relaxation curves of the two sample groups were not significantly
different. These results indicate that the post-glutaraldehyde reduction
process did not alter or weaken the mechanical properties of the tissues.
The biocompatibility of the glutaraldehyde treated bovine pericardium after
reduction by borohydride was examined in tissue culture studies. Reduced
and non-reduced tissues were cut into round disks which fit snugly in the
wells of a multi-well tissue culture plate. After the tissues w | | |